Want to see AU:ALA full AI Analyst Report?
ALA Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.13
Previous CloseN/A
Volume855.69K
Average Volume (3M)640.94K
Market Cap
AU$70.11M
Enterprise ValueAU$60.24
Total Cash (Recent Filing)AU$14.35M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.56
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,208,851,800
10 Day Avg. Volume649,115
30 Day Avg. Volume640,942
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)5.26
Price to Sales (P/S)0.00
P/FCF Ratio-10.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal Leverage And Positive EquityMinimal leverage and positive equity provide a stronger financial foundation than many early-stage biotechs. This reduces near-term solvency pressure and preserves flexibility to direct capital toward clinical development, although it does not eliminate the need for future funding.
Engineered Immune-cell Therapy PlatformArovella is focused on engineered immune-cell therapies, including CAR technologies designed to improve targeting and potency. This platform orientation can support multiple development opportunities and creates a differentiated scientific focus within cancer biotechnology over the medium term.
Improving 2026 Free Cash Flow TrendThe improvement in free cash flow versus 2025 is an encouraging directional signal within an otherwise cash-burning business. If sustained, better cash conversion could moderate funding pressure and extend development capacity, though the company remains dependent on external capital today.
Bears Say
No Scalable Commercial RevenueRevenue falling to zero indicates that Arovella has not yet established a scalable commercial base. Without meaningful product sales, the company cannot currently fund development through operating revenue, leaving future progress dependent on clinical execution and access to capital.
Persistent Operating And Net LossesRecurring, substantial operating and net losses show that the business has not reached profitability or demonstrated sustainable margins. Continued losses consume equity and increase the amount of financing required before any therapeutic program can generate commercial returns.
Sustained Operating Cash BurnPersistent operating cash outflows of roughly $6.9 million in the latest years show that core activities require ongoing funding. This limits financial independence, can constrain the pace of clinical investment, and raises the risk of dilution or other capital-raising needs.
Arovella Therapeutics Limited News
ALA FAQ
What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest share price was AU$0.06 and its highest was AU$0.13 in the past 12 months.
What is Arovella Therapeutics Limited’s market cap?
Arovella Therapeutics Limited’s market cap is AU$70.11M.
When is Arovella Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Arovella Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Arovella Therapeutics Limited overvalued?
According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued.
Does Arovella Therapeutics Limited pay dividends?
Arovella Therapeutics Limited does not currently pay dividends.
What is Arovella Therapeutics Limited’s EPS estimate?
Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arovella Therapeutics Limited have?
Arovella Therapeutics Limited has 1,208,851,800 shares outstanding.
What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arovella Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arovella Therapeutics Limited
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Technical Analysis
Imugene
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―